<DOC>
	<DOCNO>NCT01096355</DOCNO>
	<brief_summary>This phase I trial study side effect , best way give , best dose gamma-secretase inhibitor RO4929097 treat patient metastatic unresectable solid malignancy . Enzyme inhibitor , gamma-secretase inhibitor RO4929097 , may stop growth tumor cell block enzymes need cell growth .</brief_summary>
	<brief_title>Gamma-Secretase Inhibitor RO4929097 Treating Patients With Metastatic Unresectable Solid Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine safety profile 6 different administration schedule gamma-secretase inhibitor RO4929097 patient advance solid malignancy . SECONDARY OBJECTIVES : I . To determine pharmacokinetic ( PK ) parameters gamma-secretase inhibitor RO4929097 administer use 6 different administration schedule . II . To assess preliminary antitumor activity gamma-secretase inhibitor RO4929097 patient . TERTIARY OBJECTIVES : I . To assess pharmacodynamic ( PD ) effect gamma-secretase inhibitor RO4929097 Notch signal pathway tumor surrogate tissue , well soluble marker angiogenesis plasma , administer use 6 different dose schedule . ( Exploratory ) II . To evaluate relationship PK PD effect attempt define optimal biological dosing schedule ( OBDS ) provide sustain inhibition Notch signal pathway time tolerable toxicity profile . ( Exploratory ) III . To correlate inhibition Notch signal pathway measure tumor surrogate tissue preliminary antitumor activity ass potential clinical predictive value OBDS define . ( Exploratory ) IV . To assess effect various pharmacogenomic polymorphism cytochrome P450 pathway PK PD parameter . ( Exploratory ) OUTLINE : This multicenter , dose-escalation study . Patients assign 1 6 dose schedule . GROUP A : Patients receive oral gamma-secretase inhibitor RO4929097 daily day 1-3 8-10 . GROUP B : Patients receive oral RO4929097 daily day 1-7 . GROUP C : Patients receive oral RO4929097 daily day 1 , 3 , 5 , 7 , 9 , 11 , 13 , 15 , 17 , 19 , 21 . GROUP D : Patients receive oral RO4929097 daily day 1 , 8 , 15 . GROUP E : Patients receive oral RO4929097 daily day 1 , 4 , 8 , 11 , 15 , 18 . GROUP F : Patients receive oral RO4929097 daily day 1-5 , 8-12 , 15-19 . Treatment group repeat every 3 week absence disease progression unacceptable toxicity . Patients undergo tumor biopsy baseline day 15 22 first course treatment . Plasma sample collect periodically pharmacokinetic , pharmacodynamic , pharmacogenomic analysis ass level adipsin marker angiogenesis . After completion study treatment , patient follow 4 week .</detailed_description>
	<criteria>Histologically cytologically confirm solid malignancy Metastatic unresectable disease Standard curative palliative measure exist longer effective Measurable disease , define ≥ 1 lesion accurately measure ≥ 1 dimension ( long diameter record ) ≥ 20 mm conventional technique ≥ 10 mm spiral CT scan No known brain metastasis ECOG performance status ( PS ) 01 ( Karnofsky PS 70100 % ) Life expectancy &gt; 12 week Leukocytes ≥ 3,000/mm^3 ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL Total bilirubin normal AST/ALT ≤ 2.5 time upper limit normal Serum creatinine normal OR creatinine clearance ≥ 60 mL/min No uncontrolled hypocalcemia , hypomagnesemia , hyponatremia , hypophosphatemia , hypokalemia , define &lt; low limit normal despite adequate electrolyte supplementation QTc ≤ 450 msec male QTc ≤ 470 female , measure ECG use Bazett 's formula Not pregnant nursing Negative pregnancy test Fertile patient must use 2 form contraception ( i.e. , barrier contraception 1 method contraception ) ≥ 4 week , , ≥ 12 month completion study treatment Willing undergo 2 tumor biopsy ( unless medically contraindicate ) Able swallow medication No malabsorption syndrome condition would interfere intestinal absorption No diarrhea ≥ grade 2 control standard antidiarrhea medication No uncontrolled concurrent illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia chronic , stable atrial fibrillation Psychiatric illness social situation would limit compliance study requirement No history risk factor QT interval prolongation include , limited , family personal history follow : Long QT syndrome A history torsades de pointes Recurrent syncope without know etiology Sudden unexpected death Female patient may donate ovum study treatment No blood donation ≥ 12 month completion study treatment No serologic positivity hepatitis A , B , C ; history liver disease ; form hepatitis cirrhosis No HIVpositive patient combination antiretroviral therapy No history allergic reaction attribute compound similar chemical biologic composition gammasecretase inhibitor RO4929097 agent use study No concurrent agent therapy administer intent treat patient 's malignancy No prior gammasecretase inhibitor Any number prior treatment regimen allow At least 4 week since prior radiotherapy systemic therapy ( 6 week prior carmustine mitomycin C ) Exceptions may make lowdose , nonmyelosuppressive radiotherapy symptomatic palliation Recovered adverse event due prior therapy &lt; CTCAE grade 2 ( except alopecia ) No concurrent investigational agent No concurrent medication narrow therapeutic index metabolize cytochrome P450 , include warfarin sodium ( Coumadin® ) No concurrent medication strong inducers/inhibitors substrates CYP3A4 No concurrent medication food may interfere metabolism gammasecretase inhibitor RO4929097 include ketoconazole , grapefruit , grapefruit juice No antiarrhythmic concurrent medication know potential prolong QT interval</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>